- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting IDH1/IDH2 mutations in gliomas
Authors
Keywords
-
Journal
CURRENT OPINION IN NEUROLOGY
Volume 35, Issue 6, Pages 787-793
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2022-11-11
DOI
10.1097/wco.0000000000001111
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Revolumab: A phase II trial of nivolumab in recurrent IDH-mutant high-grade gliomas.
- (2022) Caroline Dehais et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
- (2022) Kristina Fanucci et al. JOURNAL OF CLINICAL ONCOLOGY
- Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
- (2022) Macarena I de la Fuente et al. NEURO-ONCOLOGY
- The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
- (2022) Atsushi Natsume et al. NEURO-ONCOLOGY
- Phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors
- (2021) Antje Wick et al. CLINICAL CANCER RESEARCH
- A vaccine targeting mutant IDH1 in newly diagnosed glioma
- (2021) Michael Platten et al. NATURE
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
- (2021) Ingo K. Mellinghoff et al. CLINICAL CANCER RESEARCH
- Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).
- (2021) Min Lu et al. JOURNAL OF CLINICAL ONCOLOGY
- The implications of IDH mutations for cancer development and therapy
- (2021) Christopher J. Pirozzi et al. Nature Reviews Clinical Oncology
- Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
- (2020) Zenon Konteatis et al. ACS Medicinal Chemistry Letters
- 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma
- (2020) Laetitia Federici et al. NEURO-ONCOLOGY
- Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
- (2020) Yuxiang Wang et al. Science Advances
- Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
- (2020) Ingo K. Mellinghoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune suppression in gliomas
- (2020) Matthew M. Grabowski et al. JOURNAL OF NEURO-ONCOLOGY
- Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
- (2020) Padma Kadiyala et al. JOURNAL OF CLINICAL INVESTIGATION
- PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
- (2019) I K Mellinghoff et al. NEURO-ONCOLOGY
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
- (2018) Lukas Bunse et al. NATURE MEDICINE
- Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
- (2018) Samuel K. McBrayer et al. CELL
- Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
- (2018) Alex Shimura Yamashita et al. NEURO-ONCOLOGY
- Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
- (2017) Sevin Turcan et al. NATURE GENETICS
- Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
- (2017) Tathiane M Malta et al. NEURO-ONCOLOGY
- Correlation of immune phenotype with IDH mutation in diffuse glioma
- (2017) Anna Sophie Berghoff et al. NEURO-ONCOLOGY
- Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy
- (2017) Tiffany R. Hodges et al. NEURO-ONCOLOGY
- 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
- (2017) Parker L. Sulkowski et al. Science Translational Medicine
- Mutation-Specific T Cells for Immunotherapy of Gliomas
- (2015) Cornelis J.M. Melief NEW ENGLAND JOURNAL OF MEDICINE
- Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
- (2015) Serena Pellegatta et al. Acta Neuropathologica Communications
- A vaccine targeting mutant IDH1 induces antitumour immunity
- (2014) Theresa Schumacher et al. NATURE
- Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer
- (2014) Supriya K. Saha et al. NATURE
- TET enzymes, TDG and the dynamics of DNA demethylation
- (2013) Rahul M. Kohli et al. NATURE
- An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
- (2013) D. Rohle et al. SCIENCE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
- (2011) M Fernanda Amary et al. JOURNAL OF PATHOLOGY
- Identification of additional IDH mutations associated with oncometabolite R(−)-2-hydroxyglutarate production
- (2011) P S Ward et al. ONCOGENE
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- Cancer-associated IDH mutations: biomarker and therapeutic opportunities
- (2010) K E Yen et al. ONCOGENE
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
- (2009) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
- (2009) Lenny Dang et al. NATURE
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
- (2009) Elaine R. Mardis et al. NEW ENGLAND JOURNAL OF MEDICINE
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search